Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bridgebio Pharma Inc
(NQ:
BBIO
)
29.52
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bridgebio Pharma Inc
< Previous
1
2
3
4
5
6
Next >
BridgeBio Pharma: Q3 Earnings Insights
November 03, 2022
BridgeBio Pharma (NASDAQ:BBIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
BridgeBio Pharma Shares Preliminary Data From Gene Therapy Candidate In Ultra Rare Disorder
October 14, 2022
Via
Benzinga
LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial
October 13, 2022
Via
Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
August 18, 2022
Via
Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
September 13, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Via
Benzinga
BridgeBio Pharma Earnings Perspective: Return On Capital Employed
August 25, 2022
According to Benzinga Pro data, during Q2, BridgeBio Pharma (NASDAQ:BBIO) posted sales of $73.75 million. Earnings were up 98.73%, but BridgeBio Pharma still reported an overall loss of $2.56 million.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 25, 2022
Via
Benzinga
BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate
July 26, 2022
Via
Benzinga
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
June 22, 2022
Via
Benzinga
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
May 26, 2022
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 18, 2022
Via
Benzinga
BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off
August 18, 2022
BridgeBio Pharma (NASDAQ: BBIO) has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by...
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 10, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 03, 2022
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
July 26, 2022
Via
Benzinga
Where BridgeBio Pharma Stands With Analysts
May 06, 2022
BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter:
Via
Benzinga
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'
May 05, 2022
Via
Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Via
Benzinga
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease
June 22, 2022
BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.
Via
Benzinga
BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial
April 04, 2022
BridgeBio Pharma Inc (NASDAQ: BBIO)
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
BridgeBio Pharma's Return On Capital Employed Insights
May 31, 2022
Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter.
Via
Benzinga
6 Analysts Have This to Say About BridgeBio Pharma
May 24, 2022
Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder
May 20, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
May 12, 2022
Via
Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
March 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
What 6 Analyst Ratings Have To Say About BridgeBio Pharma
March 16, 2022
BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.